Blockade of leukocyte function antigen-1 (LFA-1) in clinical islet transplantation

Current Diabetes Reports

Volumn 11, Issue 5, 2011, Pages 337-344

  Fotino, Carmen ^a   Pileggi, Antonello ^a,b,c  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c University of Miami College of Engineering   (United States)

Author keywords

Clinical islet transplantation; Efalizumab; Graft function; LFA 1; Type 1 diabetes

Indexed keywords

ABATACEPT; BASILIXIMAB; CALCINEURIN INHIBITOR; DACLIZUMAB; EFALIZUMAB; INSULIN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ALLOGENEIC PANCREAS ISLET TRANSPLANTATION; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; EFFECTOR CELL; GLYCEMIC CONTROL; GRAFT FAILURE; HUMAN; IMMUNOLOGICAL SYNAPSE; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE RASH; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LYMPHOCYTE DEPLETION; NEPHROTOXICITY; NOTE; PANCREAS ISLET TRANSPLANTATION; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REGULATORY T LYMPHOCYTE; TREATMENT OUTCOME;

EID: 80755128341     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-011-0214-y     Document Type: Note

References (32)

1. Pileggi A, Ricordi C, Kenyon NS, Froud T, Baidal DA, Kahn A et al. Twenty years of clinical islet transplantation at the Diabetes Research Institute-University of Miami. Clin Transpl. 2004:177-204.
2. Mineo D, Pileggi A, Alejandro R, Ricordi C. Point: steady progress and current challenges in clinical islet transplantation. Diabetes Care. 2009;32(8):1563-9. doi:10.2337/dc09-0490.
3. Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, Kneteman NM, et al. Five-year follow-up after clinical islet transplantation. Diabetes. 2005;54(7):2060-9. (Pubitemid 40911269)
4. Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 2006;355(13):1318-30. doi:10.1056/NEJMoa061267. (Pubitemid 44465460)
5. Froud T, Ricordi C, Baidal DA, Hafiz MM, Ponte G, Cure P, et al. Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience. Am J Transplant. 2005;5(8):2037-46. doi:10.1111/j.1600- 6143.2005.00957.x. (Pubitemid 41039883)
6. Pileggi A, Cobianchi L, Inverardi L, Ricordi C. Overcoming the challenges now limiting islet transplantation: a sequential, integrated approach. Ann N Y Acad Sci. 2006;1079:383-98. doi:10.1196/annals.1375.059. (Pubitemid 44968751)
7. Alejandro R, Barton FB, Hering BJ, Wease S. 2008 update from the collaborative islet transplant registry. Transplantation. 2008;86 (12):1783-8. doi:10.1097/TP.0b013e3181913f6a.
8. Posselt AM, Bellin MD, Tavakol M, Szot GL, Frassetto LA, Masharani U, et al. Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab. Am J Transplant. 2010;10(8):1870-80. doi:10.1111/ j.1600-6143.2010.03073.x.
9. Turgeon NA, Avila JG, Cano JA, Hutchinson JJ, Badell IR, Page AJ, et al. Experience with a novel efalizumab-based immunosuppressive regimen to facilitate single donor islet cell transplantation. Am J Transplant. 2010;10(9):2082-91. doi:10.1111/j.1600- 6143.2010.03212.x.
10. Nicolls MR, Gill RG. LFA-1 (CD11a) as a therapeutic target. Am J Transplant. 2006;6(1):27-36. doi:10.1111/j.1600- 6143.2005.01158.x. (Pubitemid 43382197)
11. Ostermann G, Weber KS, Zernecke A, Schroder A, Weber C. JAM-1 is a ligand of the beta(2) integrin LFA-1 involved in transendothelial migration of leukocytes. Nat Immunol. 2002;3 (2):151-8. doi:10.1038/ni755. (Pubitemid 34141445)
12. Berney T, Pileggi A, Molano RD, Poggioli R, Zahr E, Ricordi C, et al. The effect of simultaneous CD154 and LFA-1 blockade on the survival of allogeneic islet grafts in nonobese diabetic mice. Transplantation. 2003;76(12):1669-74. doi:10.1097/01. TP.0000092525.17025.D0. (Pubitemid 38032411)
13. Badell IR, Russell MC, Thompson PW, Turner AP, Weaver TA, Robertson JM, et al. LFA-1-specific therapy prolongs allograft survival in rhesus macaques. J Clin Invest. 2010;120(12):4520-31. doi:10.1172/JCI43895.
14. Gotoh M, Fukuzaki T, Monden M, Dono K, Kanai T, Yagita H, et al. A potential immunosuppressive effect of anti-lymphocyte function-associated antigen-1 monoclonal antibody on islet transplantation. Transplantation. 1994;57(1):123-6. (Pubitemid 24032749)
15. Nicolls MR, Coulombe M, Beilke J, Gelhaus HC, Gill RG. CD4- dependent generation of dominant transplantation tolerance induced by simultaneous perturbation of CD154 and LFA-1 pathways. J Immunol. 2002;169(9):4831-9. (Pubitemid 35217146)
16. Nicolls MR, Coulombe M, Diamond AS, Beilke J, Gill RG. Interferon-gamma is not a universal requirement for islet allograft survival. Transplantation. 2002;74(4):472-7. doi:10.1097/01. TP.0000026310.54443.3E. (Pubitemid 34977674)
17. Nicolls MR, Coulombe M, Yang H, Bolwerk A, Gill RG. Anti- LFA-1 therapy induces long-term islet allograft acceptance in the absence of IFN-gamma or IL-4. J Immunol. 2000;164(7):3627-34. (Pubitemid 30169816)
18. Chowdhury SA, Nagata M, Yamada K, Nakayama M, Chakrabarty S, Jin Z, et al. Tolerancemechanisms inmurine autoimmune diabetes induced by anti-ICAM-1/LFA-1 mAb and anti-CD8 mAb. Kobe J Med Sci. 2002;48(5-6):167-75. (Pubitemid 36693097)
19. Hasegawa Y, Yokono K, Taki T, Amano K, Tominaga Y, Yoneda R, et al. Prevention of autoimmune insulin-dependent diabetes in non-obese diabetic mice by anti-LFA-1 and anti-ICAM-1 mAb. Int Immunol. 1994;6(6):831-8. (Pubitemid 24183317)
20. Ninova D, Dean PG, Stegall MD. Immunomodulation through inhibition of multiple adhesion molecules generates resistance to autoimmune diabetes in NOD mice. J Autoimmun. 2004;23 (3):201-9. doi:10.1016/j.jaut.2004.07.002. (Pubitemid 40288102)
21. Arefanian H, Tredget EB, Rajotte RV, Korbutt GS, Gill RG, Rayat GR. Combination of anti-CD4 with anti-LFA-1 and anti-CD154 monoclonal antibodies promotes long-term survival and function of neonatal porcine islet xenografts in spontaneously diabetic NOD mice. Cell Transplant. 2007;16 (8):787-98. (Pubitemid 351448255)
22. Vincenti F, Mendez R, Pescovitz M, Rajagopalan PR, Wilkinson AH, Butt K, et al. A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant. 2007;7(7):1770-7. doi:10.1111/ j.1600-6143.2007.01845.x. (Pubitemid 46905435)
23. Leonardi C, Menter A, Hamilton T, Caro I, Xing B, Gottlieb AB. Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis. Br J Dermatol. 2008;158(5):1107-16. doi:10.1111/j.1365- 2133.2008.08548.x. (Pubitemid 351521472)
24. FDA US Food and Drug Administration: Safety: Raptiva (efalizumab) Feb 2009. Available at http://www.fda.gov/Safety/ MedWatch/SafetyInformation/ SafetyAlertsforHumanMedical Products/ucm149675.htm. Accessed July 5, 2011.
25. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000;343(4):230-8. doi:10.1056/ NEJM200007273430401. (Pubitemid 30490390)
26. Barshes NR, Lee TC, Goodpastor SE, Balkrishnan R, Schock AP, Mote A, et al. Transaminitis after pancreatic islet transplantation. J Am Coll Surg. 2005;200(3):353-61. doi:10.1016/j.jamcollsurg.2004.10.021. (Pubitemid 40298969)
27. Hafiz MM, Faradji RN, Froud T, Pileggi A, Baidal DA, Cure P, et al. Immunosuppression and procedure-related complications in 26 patients with type 1 diabetes mellitus receiving allogeneic islet cell transplantation. Transplantation. 2005;80(12):1718-28. (Pubitemid 43053997)
28. Rafael E, Ryan EA, Paty BW, Oberholzer J, Imes S, Senior P, et al. Changes in liver enzymes after clinical islet transplantation. Transplantation. 2003;76(9):1280-4. doi:10.1097/01. TP.0000098822.85924.4C. (Pubitemid 37430711)
29. Maffi P, Bertuzzi F, De Taddeo F, Magistretti P, Nano R, Fiorina P, et al. Kidney function after islet transplant alone in type 1 diabetes: impact of immunosuppressive therapy on progression of diabetic nephropathy. Diabetes Care. 2007;30(5):1150-5. doi:10.2337/dc06-1794. (Pubitemid 46684640)
30. Leitao CB, Cure P, Messinger S, Pileggi A, Lenz O, Froud T, et al. Stable renal function after islet transplantation: importance of patient selection and aggressive clinical management. Transplantation. 2009;87(5):681-8. doi:10.1097/TP.0b013e31819279a8.
31. Warnock GL, Thompson DM, Meloche RM, Shapiro RJ, Ao Z, Keown P, et al. A multi-year analysis of islet transplantation compared with intensive medical therapy on progression of complications in type 1 diabetes. Transplantation. 2008;86 (12):1762-6. doi:10.1097/TP.0b013e318190b052.
32. Hering BJ, Kandaswamy R, Ansite JD, Eckman PM, Nakano M, Sawada T, et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA. 2005;293(7):830-5. doi:10.1001/jama.293.7.830. (Pubitemid 40250366)